thought I'd post the news!
Nortran & ACIC In Negotiations For RSD921 Manufacturing Sublicense
Nortran Pharmaceuticals Inc. (VSE:NRT, OTCBB:NTRDF) is pleased to announce that ACIC Fine Chemicals Inc., of Mississauga, Canada has reached an agreement in principle and is negotiating the formal terms with the Company for a North American and European manufacturing license and an option on a marketing license for the Company's novel local anesthetic and antiarrhythmic compound,RSD921.
Under the terms of the proposed agreement, ACIC, a private company with international bulk pharmaceutical operations, will be responsible for scale-up and GMP (Good Manufacturing Practice) manufacturing of bulk RSD921. Methapharm Inc., an affiliate of ACIC, will carry out formulation, labeling, packaging, and marketing. In advance of the formal agreement, ACIC's European affiliate has begun work scaling up the RSD921 process for the upcoming Phase II clinical trials.
ACIC is a major supplier of bulk pharmaceuticals and fine chemicals to international and multinational pharmaceutical companies. Methapharm is a supplier of branded pharmaceuticals with a focus on hospital based products.
Nortran is a drug discovery company whose focus is pathology targeted small molecules. Nortran's current drugs in development target the ion channels responsible for life-threatening arrhythmias of the heart and for intractable pain.
ON BEHALF OF THE BOARD
Allen I. Bain, Ph.D.
President |
